Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody

Object Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark glioma tissue a fluorescent tracer must have the ability to penetrate through the blood brain barrier (BBB) and provide delineation in the tumor periphery where heterogeneously intact BBB may exist. In this study it was hypothesized that, due to its smaller size, fluorescently labeled anti-EGFR Affibody protein (∼7 kDa) would provide a more clear delineation of the tumor margin than would fluorescently labeled cetuximab, a full antibody (∼150 kDa) to the epidermal growth factor receptor (EGFR). Methods Cetuximab and anti-EGFR targeted Affibody were conjugated to two different fluorescent dyes (both emitting in the near-infrared) and injected intravenously into 6 athymic mice which were inoculated orthotopically with green fluorescent protein (GFP) expressing human U251 glioma cells. Each mouse was sacrificed at 1-h post injection, at which time brains were removed, snap frozen, sectioned and quantitatively analyzed for fluorescence distribution. Results Ex vivo analysis showed on average, nearly equal concentrations of cetuximab and Affibody within the tumor (on average Affibody made up 49±6% of injected protein), however, the cetuximab was more confined to the center of the tumor with Affibody showing significantly higher concentrations at the tumor periphery (on average Affibody made up 72±15% of injected protein in the outer 50 um of the tumor). Further ex vivo analysis of detection studies showed that the Affibody provided superior discrimination for differentiation of tumor from surrounding normal brain. Conclusions The present study indicates that fluorescently labeled anti-EGFR Affibody can provide significantly better delineation of tumor margins than a fluorescently labeled anti-EGFR antibody and shows considerable potential for guiding margin detection during neurosurgery.

[1]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[2]  Tayyaba Hasan,et al.  Diagnostic detection of diffuse glioma tumors in vive with molecular fluorescent probe-based transmission spectroscopy. , 2009, Medical physics.

[3]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[4]  G. Moore,et al.  The clinical use of fluorescein in neurosurgery; the localization of brain tumors. , 1948, Journal of neurosurgery.

[5]  J. Tonn,et al.  Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature , 2008, Brain pathology.

[6]  H Stepp,et al.  Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. , 2000, Journal of neurosurgery.

[7]  Brian W. Pogue,et al.  Image contrast in fluorescence and magnetic resonance images for glioblastoma detection , 2011, BiOS.

[8]  U. Muller-eberhard,et al.  Pathophysiology of heme synthesis. , 1988, Seminars in hematology.

[9]  P. Stewart,et al.  Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. , 1987, Journal of neurosurgery.

[10]  Kiyoshi Sato,et al.  Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas , 1995, Cancer.

[11]  Xiaoyao Fan,et al.  Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. , 2011, Journal of neurosurgery.

[12]  S. Gibbs-Strauss Noninvasive fluorescence monitoring for functional assessment of murine glioma treatment , 2008 .

[13]  P J Kelly,et al.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. , 1993, Journal of neurosurgery.

[14]  Yasuhiko Kaku,et al.  Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. , 2003, Journal of neurosurgery.

[15]  Keith D. Paulsen,et al.  Quantitative, spectrally-resolved intraoperative fluorescence imaging , 2012, Scientific Reports.

[16]  Peter Klein,et al.  A structure-based model for ligand binding and dimerization of EGF receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Toda Intraoperative navigation and fluorescence imagings in malignant glioma surgery. , 2008, The Keio journal of medicine.

[18]  A. Wu,et al.  Positive progress in immunoPET--not just a coincidence. , 2010, Cancer biotherapy & radiopharmaceuticals.

[19]  H Stepp,et al.  Fluorescence-guided resections of malignant gliomas--an overview. , 2003, Acta neurochirurgica. Supplement.

[20]  J. Mendelsohn,et al.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma , 1993, Cancer Immunology, Immunotherapy.

[21]  Xiaoyao Fan,et al.  Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. , 2011, Journal of neurosurgery.

[22]  Tayyaba Hasan,et al.  Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. , 2010, Academic radiology.

[23]  Sachio Suzuki,et al.  Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. , 2007, Neurologia medico-chirurgica.

[24]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[25]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[26]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[27]  Brian W. Pogue,et al.  High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.

[28]  Fredrik Y Frejd,et al.  Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.

[29]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  R. Dickson,et al.  The EGF receptor system as a target for antitumor therapy. , 1991, Cancer investigation.

[31]  B. Vincenzi,et al.  The biological properties of cetuximab. , 2008, Critical reviews in oncology/hematology.

[32]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Johansson,et al.  Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. , 2008, Journal of molecular biology.

[35]  Brian W. Pogue,et al.  Determination of blood plasma fluorescence extinction coefficients for dyes used in three-compartment binding model , 2011, BiOS.

[36]  W. Stummer,et al.  In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. , 1998, Journal of photochemistry and photobiology. B, Biology.

[37]  Frederic Leblond,et al.  Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. , 2011, Journal of biomedical optics.

[38]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Yang Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas , 2012 .

[40]  D. A. Hansen,et al.  Indocyanine green (ICG) staining and demarcation of tumor margins in a rat glioma model. , 1993, Surgical neurology.

[41]  Lutz Dörner,et al.  Fluorescence-Guided Surgery for Malignant Glioma: A Review on Aminolevulinic Acid Induced Protoporphyrin IX Photodynamic Diagnostic in Brain Tumors , 2010 .

[42]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[43]  M. M. el-Sharabasy,et al.  Porphyrin metabolism in some malignant diseases. , 1992, British Journal of Cancer.

[44]  Hjalmar Brismar,et al.  Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. , 2007, Nuclear medicine and biology.

[45]  Brian W. Pogue,et al.  Deferoxamine Iron Chelation Increases δ‐Aminolevulinic Acid Induced Protoporphyrin IX in Xenograft Glioma Model , 2010, Photochemistry and photobiology.

[46]  C. Nicholson,et al.  Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging. , 2004, Journal of neurophysiology.

[47]  Charles Nicholson,et al.  Diffusion and related transport mechanisms in brain tissue , 2001 .

[48]  S. Ståhl,et al.  Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry , 2009, Journal of Nuclear Medicine.

[49]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.